Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer
X Yin, H Liao, H Yun, N Lin, S Li, Y Xiang… - Seminars in cancer biology, 2022 - Elsevier
Lung cancer accounts for the main proportion of malignancy-related deaths and most
patients are diagnosed at an advanced stage. Immunotherapy and targeted therapy have …
patients are diagnosed at an advanced stage. Immunotherapy and targeted therapy have …
Liquid biopsy for lung cancer: up-to-date and perspectives for screening programs
GMS Casagrande, MO Silva, RM Reis… - International Journal of …, 2023 - mdpi.com
Lung cancer is the deadliest cancer worldwide. Tissue biopsy is currently employed for the
diagnosis and molecular stratification of lung cancer. Liquid biopsy is a minimally invasive …
diagnosis and molecular stratification of lung cancer. Liquid biopsy is a minimally invasive …
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
AJ de Langen, ML Johnson, J Mazieres… - The Lancet, 2023 - thelancet.com
Background Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRAS G12C.
We compared the efficacy and safety of sotorasib with a standard-of-care treatment in …
We compared the efficacy and safety of sotorasib with a standard-of-care treatment in …
[HTML][HTML] Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer
Acquired resistance to tyrosine kinase inhibitors (TKI), such as osimertinib used to treat
EGFR-mutant lung adenocarcinomas, limits long-term efficacy and is frequently caused by …
EGFR-mutant lung adenocarcinomas, limits long-term efficacy and is frequently caused by …
MET alterations in NSCLC—current perspectives and future challenges
J Remon, LEL Hendriks, G Mountzios… - Journal of Thoracic …, 2023 - Elsevier
Targeted therapies have revolutionized the treatment and improved the outcome for
oncogene-driven NSCLC and an increasing number of oncogenic driver therapies have …
oncogene-driven NSCLC and an increasing number of oncogenic driver therapies have …
[HTML][HTML] SMARCA4: Current status and future perspectives in non-small-cell lung cancer
Y Tian, L Xu, X Li, H Li, M Zhao - Cancer Letters, 2023 - Elsevier
SMARCA4, also known as transcription activator, is an ATP-dependent catalytic subunit of
SWI/SNF (SWItch/Sucrose NonFermentable) chromatin-remodeling complexes that …
SWI/SNF (SWItch/Sucrose NonFermentable) chromatin-remodeling complexes that …
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
M Schuler, K Cuppens, T Plönes, M Wiesweg… - Nature medicine, 2024 - nature.com
Antibodies targeting the immune checkpoint molecules PD-1, PD-L1 and CTLA-4,
administered alone or in combination with chemotherapy, are the standard of care in most …
administered alone or in combination with chemotherapy, are the standard of care in most …
FOXM1: A small fox that makes more tracks for cancer progression and metastasis
Transcription factors (TFs) are indispensable for the modulation of various signaling
pathways associated with normal cell homeostasis and disease conditions. Among cancer …
pathways associated with normal cell homeostasis and disease conditions. Among cancer …
Emerging targeted therapies in advanced non-small-cell lung cancer
S Li, GS de Camargo Correia, J Wang, R Manochakian… - Cancers, 2023 - mdpi.com
Simple Summary The discovery of actionable oncogenic driver mutations in non-small-cell
lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful …
lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful …
Small molecule inhibitors targeting the cancers
Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …